

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/41, 31/415, 31/505, 31/55, C07D 233/02, 235/22, 239/06, 239/70, 407/12, 471/04	A1	(11) International Publication Number: WO 96/14067 (43) International Publication Date: 17 May 1996 (17.05.96)
(21) International Application Number: PCT/US95/14794 (22) International Filing Date: 3 November 1995 (03.11.95) (30) Priority Data: 08/334,249 4 November 1994 (04.11.94) US (71) Applicant: CEPHALON, INC. [US/US]; 145 Brandywine Parkway, West Chester, PA 19380 (US). (72) Inventors: MALLAMO, John, P.; 616 Font Road, Glenmore, PA 19343 (US). BIHOVSKY, Ron; 804 Primrose Lane, Wynnewood, PA 19096 (US). CHATTERJEE, Sankar; 228 Henley Road, Wynnewood, PA 19096 (US). TRIPATHY, Rabindranath; 542 South Broadway #1-6, Pennsville, NJ 08070 (US). (74) Agents: MILLER, Suzanne, E. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).		(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report.</i>
(54) Title: CYSTEINE PROTEASE AND SERINE PROTEASE INHIBITORS (57) Abstract The present invention is directed to irreversible inhibitors of serine and cysteine proteases which most preferably contain a 1-oxytriazole or 1-oxyimidazole functionality. Methods for the use of the protease inhibitors are also described.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

CYSTEINE PROTEASE AND SERINE PROTEASE INHIBITORS

FIELD OF THE INVENTION

We have discovered and in this patent document we disclose novel inhibitors of cysteine or serine proteases, methods for making our novel compounds, and methods for using
5 our novel compounds. We refer to our compounds as "heterocyclic-N-hetero atom methyl ketones."

BACKGROUND OF THE INVENTION

Numerous cysteine and serine proteases have been
10 identified in human tissues. A "protease" is an enzyme which degrades proteins or peptides into smaller components. The terms "cysteine protease" and "serine protease" refer to proteases which are distinguished by the presence of a cysteine or serine residue which plays a critical role in the catalytic
15 process. Mammalian systems, including humans, normally degrade and process proteins via a variety of mechanisms including the actions of cysteine and serine proteases. However, when present at elevated levels or when abnormally activated, cysteine and serine proteases are involved in
20 pathophysiological processes.

For example, calcium-activated neutral proteases ("calpains") comprises a family of intracellular cysteine proteases which are ubiquitously expressed in mammalian tissues. Two major calpains have been identified: calpain I
25 and calpain II. While calpain II is the predominant form in

- 2 -

many tissues, calpain I is thought to be the predominant form in pathological conditions of nerve tissues. The calpain family of cysteine proteases has been implicated in many diseases and disorders, including neurodegeneration, stroke, 5 Alzheimer's disease, amyotrophy, motor neuron damage, acute central nervous system injury, muscular dystrophy, bone resorption, platelet aggregation, cataracts and inflammation. Calpain I has been implicated in excitatory amino-acid induced neurotoxicity disorders including ischemia, hypoglycemia and 10 epilepsy. The lysosomal cysteine protease cathepsin B has been implicated in the following disorders: arthritis, inflammation, myocardial infarction, tumor metastasis, and muscular dystrophy. Other lysosomal cysteine proteases include cathepsins C, H, L and S. Interleukin-1 β converting enzyme 15 ("ICE") is a cysteine protease which catalyzes the formation of interleukin-1 β . Interleukin-1 β is an immunoregulatory protein implicated in the following disorders and diseases: inflammation, diabetes, septic shock, rheumatoid arthritis, and Alzheimer's disease. ICE has also been linked to the 20 apoptotic cell death of neurons which is implicated in a variety of neurodegenerative disorders including Parkinson's disease, ischemia and amyotrophic lateral sclerosis (ALS) .

Cysteine proteases are also produced by various pathogens. The cysteine protease clostripain is produced by 25 Clostridium histolyticum. Other proteases are produced by Trypanosoma cruzi, malaria parasites Plasmodium falciparum and P. vinckei and, streptococcus strains. Hepatitis A viral protease (HAV 3) C is a cysteine protease essential for processing of picornavirus structural proteins and enzymes.

30 Exemplary serine proteases implicated in degenerative disorders include thrombin, human leukocyte elastase, pancreatic elastase, chymase and cathepsin G. Specifically, thrombin is produced in the blood coagulation cascade, cleaves fibrinogen to form fibrin and activates Factor VIII; thrombin 35 is implicated in thrombophlebitis, thrombosis and asthma. Human leukocyte elastase is implicated in tissue degenerative disorders such as rheumatoid arthritis, osteoarthritis,


- 3 -

atherosclerosis, bronchitis, cystic fibrosis, and emphysema. Pancreatic elastase is implicated in pancreatitis. Chymase, an enzyme important in angiotensin synthesis, is implicated in hypertension, myocardial infarction, and coronary heart disease. Cathepsin G is implicated in abnormal connective tissue degradation, particularly in the lung.


Given the link between cysteine or serine proteases and various debilitating disorders, compounds which inhibit these proteases would be useful and would provide an advance in both research and clinical settings.

SUMMARY OF THE INVENTION

We have developed novel cysteine and serine protease inhibitors which we refer to as "heterocyclic-N-hetero atom methyl ketones." They are represented by the following formula:



Constituent members are defined *infra*. Preferred embodiments are heterocyclic-N-oxy methyl ketones represented by the following formula:



Constituent members are defined *infra*.

Our compounds are useful for the irreversible inhibition of cysteine and serine proteases. Beneficially, the compounds find utility in a variety of settings. For example,

- 4 -


in a research arena, the claimed compounds can be used, for example, as standards to screen for natural and synthetic cysteine protease and serine protease inhibitors which have the same or similar functional characteristics as the disclosed compounds. In a clinical arena, our compounds can be used to alleviate, mediate, reduce and/or prevent disorders which are associated with abnormal and/or aberrant activity of cysteine proteases and/or serine proteases.

We also disclose methodologies for making our heterocyclic-N-hetero atom methyl ketones.

These and other features of our compounds will be set forth in expanded form as our disclosure continues.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

We have discovered novel cysteine and serine protease inhibitors which are represented by the general formula:



wherein:

M is O, NR⁷ or CR¹R², and most preferably NR⁷;

X¹ is O, S or NR⁷, and preferably O;

X² is O, S, NR⁷ or two hydrogen atoms, and preferably O;

Q is O, S or NR¹, and preferably O;

R¹ and R² are independently H, allyl having from 1 to 10 carbons, heteroaryl having from 1 to 10 carbons, alkanoyl having from 1 to 10 carbons, or aroyl, wherein the alkyl, heteroaryl, alkanoyl and aroyl groups are optionally substituted with J;

R³, R⁴, R⁵ and R⁶ are independently H, alkyl having from 1 to 10 carbons, aryl, or heteroaryl, wherein the alkyl, aryl and heteroaryl groups are optionally substituted with J;

Preferably, R¹, R² and R⁴ are H; and R³ is H, n-butyl,

- 5 -

isobutyl or benzyl;


R^7 and R^8 are independently H, alkyl having from 1 to 10 carbons, aryl, or heteroaryl, wherein the alkyl, aryl and heteroaryl groups are optionally substituted with J;

5 J is halogen, COOR^7 , R^7OCO , R^7CONH , OH, CN, NO_2 , NR^7R^8 , $\text{N}=\text{C}(\text{R}^7)\text{R}^8$, $\text{N}=\text{C}(\text{NR}^7\text{R}^8)_2$, SR^7 , OR^7 , phenyl, naphthyl, heteroaryl, or a cycloalkyl group having from 3 to 8 carbons;

G is NH_2 , NHR^1 , CH_2R^1 , $\text{CH}_2\text{C}(\text{O})\text{B}$, carbobenzyloxy-NH, succinylNH, $\text{R}^7\text{O-succinyl-NH}$, $\text{R}^7\text{OC}(\text{O})\text{NH}$, $-\text{CH}_2\text{C}(\text{O})-(\text{xanthen-9-yl})$,
 10 CH_2COR^9 where R^9 is an alkyl, aryl, or arylalkyl group of up to 13 carbons; or $\text{AA}^1\text{NHC}(\text{O})\text{OCH}_2\text{C}_6\text{H}_5$, where AA^1 is one of the 20 natural amino acids or its opposite antipode;

B is alkyl having from 1 to 10 carbons, aralkyl having from 1 to 10 carbons, aryl having 1 to 3 carbocyclic
 15 rings, or heteroaryl having 1 to 3 rings, wherein the alkyl, aralkyl, aryl and heteroaryl groups are optionally substituted with J; and

A has the structure:



wherein:

20 Y is N or CR^1 ;

W is a double bond or a single bond;


D is $\text{C}=\text{O}$ or a single bond;

E and F are independently R^1 , R^2 , J, or when taken together E and F comprise an aliphatic carbocyclic ring having
 25 from 5 to 7 carbons, an aromatic carbocyclic ring having from 5 to 7 carbons, an aliphatic heterocyclic ring having from 5 to 7 atoms, or an aromatic heterocyclic ring having from 5 to 7 atoms; wherein: the aliphatic heterocyclic ring and the aromatic heterocyclic ring each have from 1 to 4 heteroatoms;

- 6 -

and the aliphatic carbocyclic ring, the aromatic carbocyclic ring, the aliphatic heterocyclic ring, and the aromatic heterocyclic ring are each optionally substituted with J.

Preferred embodiments of the invention have the
5 formula:




wherein:

K is $\text{NHC}(\text{O})\text{OCH}_2\text{C}_6\text{H}_5$, $-\text{CH}_2\text{C}(\text{O})-(\text{xanthen-9-yl})$ or $-\text{CH}_2\text{C}(\text{O})\text{CH}(\text{C}_6\text{H}_5)\text{C}_2\text{H}_5$.

P^1 is isobutyl, isopropyl, benzyl, ethyl or
10 carboxyalkyl of 2-9 carbons; and

X^3 has the formula:



wherein:

D is $\text{C}=\text{O}$ or a single bond;

X^4 is CH , CCl , CCH_3 , CF or N ;

15 X^5 is H , CH_3 , Cl , OCH_3 or F ;

X^6 is H , CH_3 , Cl , F , OCH_3 , CF_3 , ethyl or phenyl;

X^7 is N , CCl , CH , COCH_3 or CF ; and

Y is N or CH .

In some preferred embodiments, K is $-\text{CH}_2\text{C}(\text{O})-$.


- 7 -

(xanthen-9-yl) or carbobenzyloxy-NH, and in other preferred embodiments, P¹ is benzyl, isobutyl or ethyl.

In further preferred embodiments Y is N. Preferably, X³ is O-1-oxybenzotriazole, or X⁷ is N, or Y is CH, or Y is N
5 and D is C=O.

In some embodiments Q is NR¹, or R³ and R⁴ are both not H. In other embodiments one of R¹ or R² is a group other than H. In further embodiments, X¹ is S or NR⁷, or M is O or CR¹R².

10 In other embodiments X² is S, NR¹, or two hydrogen atoms, or K has the formula:



As used herein, the term "alkyl" is meant to include straight-chain, branched and cyclic hydrocarbon groups such as, for example, ethyl, isopropyl and cyclopropyl groups.
15 Preferred alkyl groups have 1 to about 10 carbon atoms. "Cycloalkyl" groups are cyclic alkyl groups. "Aryl" groups are aromatic cyclic compounds including but not limited to phenyl, tolyl, benzyl, naphthyl, anthracyl, phenanthryl, pyrenyl, and xylyl. The term "carbocyclic," as used herein, refers to
20 cyclic groups in which the ring portion is composed solely of carbon atoms. The term "heterocyclic" refers to cyclic groups in which the ring portion includes at least one heteroatom such as O, N or S. "Heteroalkyl" groups are heterocycles containing solely single bonds within their ring portions, i.e. saturated
25 heteroatomic ring systems. "Alkanoyl" groups are those which contain an alkyl portion linked through a carbonyl group. "Aroyl" groups are those which contain an aryl portion linked through a carbonyl group. "Aralkyl" groups have both aryl and

- 8 -

alkyl portions, and are attached through their alkyl portions.

Because the disclosed compounds are useful in inhibiting the activity of serine and cysteine proteases, and because the usefulness of such compounds can be applied to both research and therapeutic settings, methodologies for inhibiting the activity of cysteine and serine proteases by contacting the protease with a compound of the invention include providing the compound to a mammal, including a human, as a medicament or pharmaceutical agent.

As used herein, the term "contacting" means directly or indirectly causing at least two moieties to come into physical association with each other. Contacting thus includes physical acts such as placing the moieties together in a container, or administering moieties to a patient. Thus, for example, administering a compound of the invention to a human patient evidencing a disease or disorder associated with abnormal and/or aberrant activity of such proteases in a method for inhibiting the enzymatic activity of such protease which are associated with disease or disorder, falls within the scope of the definition of the term "contacting."

As used herein, the terms "inhibit" and "inhibition" mean having an adverse effect on enzymatic activity. The term "irreversible," when used to modify "inhibit" and "inhibition," means that such adverse effect on catalytic activity can not be reversed once it is initiated. Inhibition of cysteine or serine protease activity can be determined using a variety of methodologies. Two convenient methodologies are preferred. The first involves determining the rate of inactivation of a protease using a compound of the invention; the second involves determining the percent inhibition of a defined amount of the protease by a compound of the invention. With respect to the cysteine protease calpain I, a whole cell assay, which measures inhibition of calpain I activity via a decrease in the amount of cleavage of a preferred calpain I substrate, α -spectrin, is also useful in determining the inhibition of catalytic activity.

In a research environment, preferred compounds having

- 9 -

defined attributes can be used to screen for natural and synthetic compounds which evidence similar characteristics of inhibiting protease activity. The compounds can also be used in the refinement of *in vitro* and *in vivo* models for
5 determining the effects of inhibition of particular proteases on particular cell types or biological conditions.

Pharmaceutically acceptable salts of the cysteine and serine protease inhibitors also fall within the scope of the compounds as disclosed herein. The term "pharmaceutically
10 acceptable salts" as used herein means an inorganic acid addition salt such as hydrochloride, sulfate, and phosphate, or an organic acid addition salt such as acetate, maleate, fumarate, tartrate, and citrate. Examples of pharmaceutically acceptable metal salts are alkali metal salts such as sodium
15 salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt. Examples of pharmaceutically acceptable ammonium salts are ammonium salt and tetramethylammonium salt. Examples of pharmaceutically acceptable organic amine addition salts are
20 salts with morpholine and piperidine. Examples of pharmaceutically acceptable amino acid addition salts are salts with lysine, glycine, and phenylalanine.

Compounds provided herein can be formulated into pharmaceutical compositions by admixture with pharmaceutically
25 acceptable nontoxic excipients and carriers. The compositions may be prepared for use in parenteral administration, particularly in the form of liquid solutions or suspensions; or oral administration, particularly in the form of tablets or capsules; or intranasally, particularly in the form of powders,
30 nasal drops, or aerosols; or dermally, via, for example, transdermal patches; or prepared in other suitable fashions for these and other forms of administration as will be apparent to those skilled in the art.

The composition may conveniently be administered in
35 unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in *Remington's Pharmaceutical Sciences* (Mack Pub. Co., Easton, PA,

- 10 -

1980). Formulations for parenteral administration may contain as common excipients sterile water or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like. In particular, 5 biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful excipients to control the release of the active compounds. Other potentially useful parenteral delivery systems for these active compounds include ethylene-vinyl 10 acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation administration contain as excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, 15 or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Formulations for parenteral administration may also include glycocholate for buccal administration, a salicylate for rectal administration, or citric acid for vaginal administration. Formulations for 20 transdermal patches are preferably lipophilic emulsions.

The materials of this invention can be employed as the sole active agent in a pharmaceutical or can be used in combination with other active ingredients.


The concentrations of the compounds described herein 25 in a therapeutic composition will vary depending upon a number of factors, including the dosage of the drug to be administered, the chemical characteristics (e.g., hydrophobicity) of the compounds employed, and the route of administration. In general terms, the compounds of this 30 invention may be provided in an aqueous physiological buffer solution containing about 0.1 to 10% w/v. compound for parenteral administration. Typical dose ranges are from about 1 μ g/kg to about 1 g/kg of body weight per day; a preferred dose range is from about 0.01 mg/kg to 100 mg/kg of body weight 35 per day. The preferred dosage of drug to be administered is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health

- 11 -

status of the particular patient, the relative biological efficacy of the compound selected, and formulation of the compound excipient, and its route of administration.

The compounds of the invention are mechanism-based irreversible inhibitors of cysteine and serine proteases which we believe, although not wishing to be bound thereby, provide a novel mechanism of protease inactivation. The inhibitors most preferably contain a 1-oxytriazole, 3-oxytriazin-4-one, or 1-oxyimidazole functionality. It has been found that the compounds of the invention are irreversible inhibitors. While not wishing to be bound by any specific theory, it is believed that linkage through the N-hetero, preferably N-oxy bond, makes the 1-oxytriazole, 3-oxytriazin-4-one, or 1-oxyimidazole moiety a superior leaving group, thus facilitating inactivation upon interaction with the target protease. Scheme 1 depicts a proposed mechanism of inactivation of a cysteine protease by an inhibitor of the invention:

Scheme 1



- 12 -

The invention is further illustrated by way of the following examples which are intended to elucidate the invention. These examples are not intended, nor are they to be construed, as limiting the scope of the disclosure nor
5 the appended claims.

Example 1A:**Inhibition and Rate of Cysteine Protease Activity**

To evaluate inhibitory activity of our compounds, stocks (40 times concentrated) of each compound to be tested
10 were prepared in 100% anhydrous dimethyl sulfoxide (DMSO) and 5 μ l of each inhibitor preparation was aliquoted into each of three wells of a 96 well plate. Calpain I was purified from human red blood cells using a modification of the method described by Lee, W.J. et al. (Biochem.
15 Internatl. (1990)22(1): 163-171). Briefly, 3 units of packed outdated red blood cells were washed 3x by repeated centrifugation at 500rpm for 10 minutes through 900mls of 0.9% NaCl. Cells were lysed in 20mM Tris/1mM EDTA/1mM EGTA/5mM mercaptoethanol (Buffer A) and centrifuged for 1
20 hour at 12,000 rpm in a GSA rotor using a Sorval centrifuge. The supernatant was collected and applied to a DEAE-sepharose FF column equilibrated in Buffer A + 25mM NaCl. After washing the column in Buffer A + 25mM NaCl, the bound protein was eluted at 117ml/hr with a 25mM to 150mM NaCl
25 linear gradient in Buffer A collecting 200, 10ml fractions. Two μ l of every fifth fraction was applied to nitrocellulose using a dot blot apparatus and calpain containing fractions identified by Western analysis. For detection of calpain, nitrocellulose sheets were first blocked in 5% Blotto (5%
30 Carnation instant milk/10mM Tris/150mM NaCl) for 30 minutes, followed by incubation for 1 hour in antibody directed against Calpain I (rabbit anti-human calpain I polyclonal sera, 1:1000 dilution in 5% Blotto). After three 5 minutes washes in 10mM Tris/150mM NaCl/.05% Tween 20 the
35 nitrocellulose was incubated for 1 hour in secondary alkaline phosphatase conjugated antibody (Biorad Cat#170-

- 13 -

6518 1:2000 in 5% Blotto). After three 5 minutes washes in 10mM Tris/150mM NaCl/.05% Tween 20 and 1 wash in 10mM Tris/150mM NaCl the nitrocellulose was incubated for up to 2 hours in a colorimetric substrate solution (Biorad Alkaline Phosphatase Substrate conjugate kit, cat#170-6432). The reaction was stopped by washing in water. After fractions containing calpain, and those in between, were pooled, solid ammonium sulfate was added to achieve a 30% solution and the mixture stirred for 1 hour at 4°C. Following collection of the precipitate by centrifugation for 1 hour at 4°C at 12K rpm in a GSA rotor, the supernatant was collected and brought to 45% in ammonium sulfate. After stirring for 1 hour at 4°C, centrifugation was repeated. The supernatant was discarded and the precipitate resuspended in approximately 7mls and dialyzed overnight at 4°C against Buffer A + 50mM NaCl. The sample was then applied to a S300 gel filtration column preequilibrated in Buffer A + 50mM NaCl, washed and eluted at a flow rate of 20ml/hr, collecting 200, 4 ml fractions. The peak of calpain was determined by assaying aliquots of every fifth fraction for enzyme activity monitored by the hydrolysis of a fluorogenic dipeptide substrate as described below. The peak fractions were pooled and the enzyme preparation used to test compounds for inhibitory activity. As an alternate to enzyme isolated from tissue sources, recombinant human calpain I has also been used to monitor compounds for inhibitory activity.

The foregoing enzyme preparation was diluted into assay buffer (i.e., 50mM Tris, 50mM NaCl, 1mM EDTA, 1mM EGTA, and 5mM β mercaptoethanol, pH 7.5 including 0.2mM Succ-Leu-Tyr-MNA) and 175 μ l aliquoted into the same wells containing the independent inhibitor stocks as well as to positive control wells containing 5 μ l DMSO, but no compound. To start the reaction, 20 μ l of 50mM CaCl₂ in assay buffer was added to all wells of the plate, excepting three, which were used as background signal baseline controls. Substrate hydrolysis was monitored every 5 minutes for a total of 30 minutes using Flouroskan II (ex=340nm; em=430nm). Substrate

- 14 -

hydrolysis in the absence of inhibitor was linear for up to 15 minutes.

To demonstrate activity against two other cysteine proteases, cathepsin B (Calbiochem, cat#219364) and cathepsin L (Calbiochem, cat#219402), assays were performed substantially the same as outlined above except that the cathepsin B and cathepsin L were diluted into a different assay buffer consisting of 50mM sodium acetate (pH 6.0)/1mM EDTA/1mM dithiothreitol and 2 the substrate used was Cbz-Phe-Arg-AMC (Bachem cat# I-1160; 0.1mM for cathepsin B; .006mM for cathepsin L). Additionally, the order of reagents added to the plate was altered because both enzymes are constitutively active. Following inhibitor addition to the plates appropriate 2x concentrated stock dilutions of the enzyme preparations were made in assay buffer and 100ul added to each well. The assay was initiated by addition of 100ul of 2x concentrated stock dilution of substrate in assay buffer. Substrate hydrolysis was monitored using a Fluoroskan II (ex=390nm; em=460nm).

Inhibition of enzyme activity was calculated as the percent decrease in the rate of substrate hydrolysis in the presence of inhibitor (v_i) relative to the rate in its absence (v_o). Comparison between v_o and v_i was made within the linear range-for substrate hydrolysis. For screening, compounds were tested at 10 μ M. Compounds having $\geq 50\%$ inhibition at 10 μ M were considered active. Apparent second order rate constants were determined from analysis of reaction progress curves under pseudo-first order conditions. Each determination represents the mean of three or more independent single cuvette analyses continually monitored via a Perkin-Elmer LS50B spectrofluorimeter. The rate of inhibition of hydrolysis was obtained by fitting the curve to the exponential equation (1):

$$y = Ae^{-k_{obs}t} + B \quad (1)$$

where y (P_t) is the product formed at time t . A and B are

- 15 -


constants. A, the amplitude of the reaction, is given by $[P_o - P\alpha]$ and B ($= P\alpha$) is the maximal product formed when the reaction is determined as $k_{obs}/[I]$. This was corrected for the presence of equation (2):

$$5 \qquad k_2 = k_{app} (1 + [S]/K_m) \qquad (2)$$

Values for k_2 are provided in Table IA.

- 16 -

Table IA



Compound of Example:		X3	P ₁ K k ₂ × 10 ³ (M ⁻¹ s ⁻¹) <u>A*B*C*</u>
5	3	1-oxybenzotriazole	BenzylZNH 150 100117
	4	1-oxybenzotriazole	i-ButylZNH 175 19
	5	1-oxybenzotriazole	EthylZNH633000443
	6	3-oxy-(3H)-triazolo[4,5-b]pyridine	BenzylZNH 184 40107
	7	6-trifluoromethyl-1-oxybenzotriazole	BenzylZNH 160 18
10	8	6-chloro-1-oxybenzotriazole	BenzylZNH 101
	9	6-methoxy-1-oxybenzotriazole	BenzylZNH 125 52
	10	6-fluoro-1-oxybenzotriazole	BenzylZNH 50
	11	6-chloro-5-methyl-1-oxybenzotriazole	BenzylZNH 98 28
	12	4-methyl-1-oxybenzotriazole	BenzylZNH 46
15	13	5-chloro-6-methyl-1-oxybenzotriazole	BenzylZNH 116 29
	14	4-chloro-1-oxybenzotriazole	BenzylZNH 157
	15	6-phenyl-1-oxybenzotriazole	BenzylZNH 77 16
	16	4,5,6,7-tetrafluoro-1-oxybenzotriazole	BenzylZNH 93
	17	5-chloro-1-oxybenzotriazole	BenzylZNH 164
20	18	5,6-dichloro-1-oxybenzotriazole	BenzylZNH 65115
	19	1-oxy-(1H)-triazolo[4,5-b]pyridine	BenzylZNH 57
	20	4,5,6,7-tetrachloro-1-oxybenzotriazole	BenzylZNH 1.3
	21	4,6,7-trichloro-1-oxybenzotriazole	BenzylZNH 1.8 10
	22	1-oxybenzimidazole	BenzylZNH 4
25	23	4,5-dichloro-1-oxybenzotriazole	BenzylZNH 64
	24	5-chloro-6-ethyl-1-oxybenzotriazole	BenzylZNH 84 30
	25	4,5-difluoro-1-oxybenzotriazole	BenzylZNH 67300
	26	6-methyl-1-oxybenzotriazole	BenzylZNH 112
	27	5-methyl-1-oxybenzotriazole	BenzylZNH 230
30	28	3-oxybenzotriazin-4-one	BenzylZNH 122 70 7
	29	5,7-dimethoxy-3-oxybenzotriazin-4-one	BenzylZNH 171
	30	6-chloro-3-oxybenzotriazin-4-one	BenzylZNH 180

- 17 -

Table IA (continued)

	Compound of Example:	X3	P ₁ K	k ₂ × 10 ³ (M ⁻¹ s ⁻¹)
			A [*] B [*] C [*]	
5	31	3-oxybenzotriazin-4-one	i-ButylZNH	46
	..			
	39	1-oxybenzotriazole	BenzylL	46 55
	40	1-oxybenzotriazole	i-ButylL	2.7 48
	..			
10	46	1-oxybenzotriazole	BenzylW	3
	.	A = Calpain I; B = Cathepsin L; C = Cathepsin B		
	..	Examples 32-38 and 41-45 are synthetic intermediates in the preparation of the compounds of examples 39- 40 and 46, respectively.		

Example 1B: Inhibition of Serine Protease Activity

15 To demonstrate activity against the serine protease α -chymotrypsin (Sigma Chem. Co. cat# C-3142) the protocol of Example 1A was followed except that the enzyme was diluted into assay buffer consisting of 50mM Hepes (pH 7.5)/0.5M NaCl and the final substrate concentration used

20 was 0.03mM Succ-Ala-Ala-Pro-Phe-AMC (Bachem, Inc. Cat# 1-1465). Additionally, because α -chymotrypsin is not a calcium sensitive enzyme and is constitutively active, following addition of inhibitor stocks to the 96 well plates, 100ul of a 2 fold concentrated stock of enzyme in

25 dilution buffer was first added and the reaction started by addition of 100ul of a 2 fold concentrated stock of substrate in assay buffer. Substrate hydrolysis was monitored every 5 minutes up to 30 minutes using a Fluoroskan II (em=390nm ex=460nm). Results, expressed as %

30 inhibition of α -chymotrypsin at 10 μ M, are presented in Table IB.

- 18 -

Table IB

Compound of Example: % Inhibition of α -
Chymotrypsin at 10 μ M

	3	86
5	5	34
	6	81
	7	99
	9	83
	10	89
10	11	100
	12	94
	22	91
	28	82
	39	100
15	40	100

Example 1C: Inhibition of Calpain Activation in Intact Cells

Sodium Dodecyl/Sulfate-Polyacrylamide Gel

Electrophoresis (SDS/PAGE)/Coomassie stain/Densitometric analysis of calpain cleavage of endogenous substrates has served as a standard method for measuring inhibition of calpain activation in intact cell systems following exposure to calcium and ionophore (Mehdi et al., 1988, *Biochem. Biophys. Res. Commun.*, 157:1117-1123; McGowan et al., 1989, *Biochem. Biophys. Res. Commun.* 158:432-435; Hayashi et al., 1991, *Biochem. Biophys. Acta.* 1094:249-256). In our analysis, we monitored the degradation of a preferred calpain substrate, the α -subunit of non-erythrocyte spectrin, using two independent antibodies which recognize the two 150 kDa cleavage products specifically generated by calpain proteolysis (Roberts-Lewis et al., 1994, *J. Neurosci.* 14:3934-3944). The use of these antibodies has greatly facilitated the evaluation of calpain inhibition in intact cell systems. For intact cell assays, the human

- 19 -

lymphoid cell line Molt-4, in which the calpain I isozyme predominates (Deshpande et al., 1993, *Neurochem. Res.* 18: 767-773) was chosen for inhibitor screening. The effectiveness of our compounds in intact Molt-4 cells is measured as a decrease in the amount of calpain-generated spectrin breakdown products compared to the amount generated in the presence of calcium and ionophore alone. Molt-4 cells were first washed and subsequently resuspended in Hepes-Buffered Saline (5.4mM KCl, 120mM NaCl, 25mM glucose, 1.5mM MgSO₄, 1mM sodium pyruvate, 20 mM Hepes pH 7.0) to 1x10⁷ cells/ml. Test compounds were first solubilized in DMSO to 50mM and subsequently diluted into Hepes-Buffered saline to a final concentration of 200μM maintaining 8% DMSO final concentration. Five microliters of inhibitor stock solutions (200μM) were then aliquoted into each of three wells of a 96 well microliter plate, followed by 100μl of cell suspension. Routinely, cells were preincubated with 40μM inhibitor for 10 minutes. Subsequently, 100μl of Hepes-buffered saline solution containing 20μM calcium ionophore (ionomycin (Sigma, St. Louis, MO, I-0634)) and 5mM CaCl₂ was added to the cells and allowed to incubate for up to 30 minutes. The calcium was then chelated by addition of 2μl of 1M EDTA and the cells were harvested by centrifugation in a Beckman table top centrifuge. The supernatant was removed and the cells lysed by addition of 20mM Tris-HCl pH 8.0/1% NP-40/.137M NaCl/13mM EDTA/10μg/ml aprotinin/10μg/ml leupeptin/.1M PMSF. Insoluble material is removed by centrifugation and the protein concentration of

- 20 -

the lysates determined by a BCA micro protein assay (Pierce, Inc., Rockford, IL). Twenty micrograms of each sample was then applied to a 6% SDS-PAGE gel and electrophoresed for 45min at 200V (Laemmli, U.K. 227 Nature 680, 1970).

- 5 Electrophoresed protein is then transferred to nitrocellulose (Towbin, H et al. 76 PNAS 4350, 1979). For detection of spectrin breakdown products, nitrocellulose sheets were first blocked in 5% Blotto (5% Carnation instant milk/10mM Tris/150mM NaCl, pH 8.0) for 30 minutes, followed
- 10 by incubation for 1 hour in antibody directed against spectrin breakdown products (Ab 38 and/or 41; Roberts Lewis et al., J. Neurosci 14, 3934-3944, 1994, 1:500 dilution in 5% Blotto). After three 5 minute washes in 10mM Tris/150mM NaCl/.05% Tween 20 the nitrocellulose is incubated for 1
- 15 hour in secondary alkaline phosphatase conjugated antibody (Biorad, Hercules CA Cat# 170-6518 1:2000 in 5% Blotto). After three 5 minutes washes in 10mM Tris/150mM NaCl/.05% Tween 20 and 1 wash in 10mM Tris/150mM NaCl the nitrocellulose is incubated for up to 2 hours in a
- 20 colorimetric substrate solution (Biorad Alakaline Phosphatase Substrate conjugate kit cat#170-6432). The reaction is stopped by washing in water. After the nitrocellulose sheets are dried the amount of spectrin breakdown products detected is quantified using a BioQuant-
- 25 Osk image analysis system (R&M Biometrics, Inc., Nashville, TN). The amount of breakdown products in compound treated cells is compared relative to the amount in non-compound treated cells and expressed as the % inhibition of breakdown

- 21 -

products ("BDPs"). Results are presented in Table IC.

- 22 -

TABLE IC

Compound of Example: % Inhibition of
BDPs (10 μ M)

5	3	67
	4	57
	5	56
	6	63
	8	57
10	16	64
	19	54
	22	61
	25	52
	28	68

Synthesis of Exemplary Compounds

15 HPLC analysis and purification of final products and intermediates was conducted under the conditions described in each example using a VyDac reverse-phase C-18 10 micron column (1.0 x 25 cm) at a flow rate of 3.5 ml/min. coupled to a UV detector.

20 The use of Ag₂O in the alkylation of alcohols is described in T.W. Greene et al., *Protective Groups in Organic Synthesis*, New York, N.Y. John Wiley & Sons, Dec. 1991, pp. 15 and 48.

Starting materials:

25 1-Hydroxybenzotriazole can be purchased from various commercial sources (e.g., Aldrich Chemical Company) and was used as received. All other benzotriazoles were prepared according to the procedures described in Brady, O. L. et al., *J. Chem. Soc.* 37, 2258-2267 (1960) ; König, W. et al., *Chem. Ber.* 103, 788-798 (1970); and Carpino, L. A., *J. Am. Chem. Soc.* 115, 4397-4398 (1993). 1-Hydroxybenzimidazole was prepared according to Seng, F. et

30

- 23 -


al., *Synthesis* 1975, page 703. Leucine chloromethylketone and phenylalanine chloromethylketone can be purchased from various commercial sources (e.g., BACHEM Bioscience, Inc.) and were used as received. Amino acid or N-terminal

5 protected dipeptide bromomethyl ketones were prepared from the corresponding diazomethylketones by treatment with HBr/AcOH or HBr (gas) according to the standard procedures cited and described in Harbeson, S.L. et al., *J. Med. Chem.* 32, 1378-1392 (1989).


10 **Example 2**

Methods A and B are general methods for preparing compounds of the invention from halomethylketones 1 and 2.

Dipeptide halomethylketone 1: m.p. 135.5-136.5°C



15 and dipeptide halomethylketone 2: m.p. 103-104°C



- 24 -


Method A: To a solution of the appropriate bromo or iodoketone (0.05-0.1 mmol) and an N-hydroxyheterocycle (1.1 eq.) in 1 mL of dimethylformamide was added Ag_2O (1.1 - 2.2 eq.) under inert atmosphere. The reaction mixture was stirred at room temperature minimizing exposure to light for 0.5-72h. The mixture was then diluted with ethyl acetate and filtered through a pad of diatomaceous earth. The filter pad was thoroughly washed with ethyl acetate and the combined filtrates were washed twice with 1 volume of H_2O and 1 volume of brine. After drying over anhydrous magnesium sulfate, and filtration, the solvent was removed under reduced pressure. The desired product was isolated and purified by HPLC as described for each example.

Method B: To a solution of the appropriate bromoketone (0.1-0.15 mmol) in dry dimethylformamide was added anhydrous potassium fluoride (3.5 eq.), and the mixture was stirred at room temperature for approximately 5 min under an inert atmosphere. An N-hydroxyheterocycle (1.2 eq.) was added, and the resulting mixture was stirred for 24h. The reaction mixture was diluted with ethyl acetate, washed successively with 1 volume each of water, saturated aqueous NaHCO_3 , 10% aqueous citric acid, water and finally with brine. After drying over magnesium sulfate, and filtration, the solvent was removed under reduced pressure. The desired product was isolated and purified by flash chromatography and/or HPLC.

- 25 -

Example 3

1- [N- [N-Benzylloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-oxobutyl]oxy]benzotriazole.



5 Method A; reaction time 19h; purification: flash chromatography (hexane:ethyl acetate 1:1) followed by HPLC (reverse phase, acetonitrile:water (containing 0.1% trifluoroacetic acid) 10%-100% over 40 min) R_t 30.10 min; yield 66%; mp 128.5-130°C; ^1H NMR (300 MHz, CDCl_3): δ 8.00 (d, 1H), 7.83 (d, 1H), 7.56 (t, 1H), 7.43 (t, 1H), 7.38-6.98' (m, 10H), 6.57 (m, 1H), 5.29 (bd, 1H), 5.06-4.9 (s overlapping with m, 4H), 4.76 (q, 1H), 4.12 (m, 1H), 3.00 (m, 2H), 1.7-1.3 (series of m, 3H), 0.98 (m, 6H); FABMS m/z 544 (MH^+); Anal. C (66.23), H (6.07), N (12.83); calc. c (66.29), H (6.07), N (12.89).


10

15

Example 4

1- [N- [N-Benzylloxycarbonyl-L-leucyl]-3S-5-methyl-3-amino-2-oxohexyl]oxy]benzotriazole.


- 26 -



Method B; reaction time 24h; purification: flash chromatography (hexane:ethyl acetate 1:1) followed by HPLC
 5 (reverse phase, acetonitrile:water (containing 0.1% trifluoroacetic acid) 10%-100% over 40 min) R_t 29.31 min; yield 43%; ^1H NMR (300 MHz, CDCl_3): δ 7.96 (m, 1H), 7.81 (bd, 1H), 7.53, m, 1H), 7.44-7.16 (m, 6H), 6.7 (bd, 1H), 5.41 (m, 2H), 5.24-5.00 (s overlapping with m, 3H), 4.62 (m, 1H),
 10 4.18 (m, 1H), 1.72-1.35 (m, 6H), 0.92 (m, 12H); FABMS m/z (510, MH^+).

Example 5

1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-3-amino-2-oxopentyloxy] benzotriazole.




15

- 27 -

Method A; reaction time 19h; purification flash chromatography (hexane:ethyl acetate 1:1) followed by HPLC (reverse phase, acetonitrile:water (containing 0.1% trifluoroacetic acid) 10%-100% over 40 min) R_t 30.10 min; yield 24%; ^1H NMR (300 MHz, CDCl_3): δ 7.98 (d, 1H), 7.83 (bd, 1H), 7.53 (m, 1H), 7.38 (m, 1H), 7.30 (s, 5H), 6.69 (b d, 1H), 5.40 (s, 2H), 5.15 (d, 1H), 5.07 (s, 2H), 4.58 (m, 1H), 4.15 (m, 1H), 1.90 (m, 1H), 1.75-1.4 (m, 4H), 0.92 (m, 6H), 0.83 (bt, 3H); FABMS m/z (482, MH^+).

10 **Example 6**

3-[N-[N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-oxobutyloxy]-3H-triazolo[4,5-b]pyridine.




Method A; reaction time: 18h; yield 36%; purification: HPLC (reverse phase, acetonitrile:water (containing 0.1% trifluoroacetic acid) 10%-100% over 40 min) R_t : 28.25 min; ^1H NMR (300 MHz, CDCl_3): δ 8.78 (m, 1H), 8.44 (bd, 1H), 7.49 (m, 1H), 7.44-7.12 (m, 10H), 6.83 (m, 1H), 5.43-5.00 (m, 6H), 4.16 (m, 1H), 3.35-3.05 (m, 2H), 1.69-1.35 (m, 3H), 0.92 (m, 6H); FABMS m/z (545, MH^+)

- 28 -

Example 7


1- [N- [N-Benzyloxycarbonyl-L-leucyl] -3S-4-phenyl-3-amino-2-oxobutyloxy] -6'-trifluoromethylbenzotriazole.



5 Method A; reaction time: 15h; yield 12%;
 purification: HPLC (reverse phase, acetonitrile:water
 (containing 0.1% trifluoroacetic acid) 10%-100% over 40 min)
 R_t : 32.90 min; ^1H NMR (300 MHz, CDCl_3): δ 8.23 (s, 1H), 8.10
 (d, 1H), 7.63 (d, 1H), 7.43-6.86 (m, 10H), 6.52 (m, 1H),
 10 5.33 (m, 1H), 5.15-4.86 (s overlapping with m, 4H), 4.69 (m,
 1H), 4.09 (m, 1H), 2.95 (m, 2H), 1.66-1.26 (m, 3H), 0.89 (m,
 6H); FABMS m/z (612, MH^+).

Example 8

1- [N- [N-Benzyloxycarbonyl-L-leucyl] -3S-4-phenyl-3-amino-2-oxobutyloxy] -6'-chlorobenzotriazole.




- 29 -

Method A; reaction time: 15h; yield 30%;
 purification: HPLC (reverse phase, acetonitrile:water
 (containing 0.1% trifluoroacetic acid) 10%-100% over 40 min)
 R_t : 32.21 min; ^1H NMR (300 MHz, CDCl_3): δ 7.90 (m, 2H), 7.46-
 5 6.95 (m, 11H), 6.60 (m, 1H), 5.29 (m, 1H), 5.18-4.89 (m,
 4H), 4.72 (m, 1H), 4.09 (m, 1H), 2.97 (m, 2H), 1.67-1.3 (m,
 3H), 0.89 (m, 6H); FABMS m/z (578, MH^+).

Example 9

1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-
 10 oxobutyloxy]-6'-methoxybenzotriazole.




Method A; reaction time: 49h; yield 7.5%;
 purification: HPLC (reverse phase, acetonitrile:water
 (containing 0.1% trifluoroacetic acid) 10%-100% over 40 min)
 15 R_t : 31.55 min; ^1H NMR (300 MHz, CDCl_3): δ 7.82 (dd, 1H), 7.46-
 6.85 (m, 12H), 6.60 (m, 1H), 5.29 (m, 1H), 5.15-4.9 (m, 4H),
 4.80 (m, 1H), 4.12 (m, 1H), 3.93 (s, 3H), 3.03 (m, 2H),
 1.67-1.32 (m, 3H), 0.86 (m, 6H); FABMS m/z (574.5, MH^+).

Example 10

20 1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-

- 30 -

oxobutyloxy]-6'-fluorobenzotriazole.



Method A; reaction time: 15h; yield 48%;

purification: HPLC (reverse phase, acetonitrile:water

5 (containing 0.1% trifluoroacetic acid) 10%-100% over 40 min)

 R_t : 31.33 min; ^1H NMR (300 MHz, CDCl_3): δ 7.98 (m, 2H), 7.52

(bd, 1H), 7.43-7.09 (m, 10H), 6.69 (m, 1H), 5.29 (m, 1H),


5.18-4.89 (m, 4H), 4.72 (m, 1H), 4.13 (m, 1H), 3.00 (m, 2H),

1.66-1.29 (m, 3H), 0.89 (m, 6H); FASMS m/z (562, MH^+)

- 31 -

Example 11


1- [N- [N-Benzyloxycarbonyl-L-leucyl] -3S-4-phenyl-3-amino-2-oxobutyloxy] -6'-chloro-5'-methylbenzotriazole.



5 Method A; reaction time: 15.5h; yield 37%;
 purification: HPLC (reverse phase, acetonitrile:water
 (containing 0.1% trifluoroacetic acid) 10%-100% over 40 min)
 R_t : 32.53 min; ^1H NMR (300 MHz, CDCl_3): δ 7.87 (s, 1H), 7.83
 (s, 1H), 7.43-6.92 (m, 10H), 6.58 (m, 1H), 5.26 (m, 1H),
 10 5.15-4.89 (m, 4H), 4.72 (m, 1H), 4.12 (m, 1H), 2.98 (m, 2H),
 2.53 (s, 3H), 1.63-1.32 (m, 3H), 0.89 (m, 6H), FABMS m/z
 (592, MH^+).

Example 12

1- [N- [N-Benzyloxycarbonyl]-L-leucyl] -3S-4-phenyl-3-amino-2-oxobutyloxy] -4'-methylbenzotriazole.




SUBSTITUTE SHEET (RULE 26)

- 32 -

Method A; reaction time: 15.5h; yield 15%;
 purification: HPLC (reverse phase, acetonitrile:water
 (containing 0.1% trifluoroacetic acid) 10%-100% over 40 min)
 R_t : 32.63 min; ^1H NMR (300 MHz, CDCl_3): δ 7.61 (d, 1H), 7.52-
 5 6.92 (m, 12H), 6.55 (m, 1H), 5.26 (m, 1H), 5.15-4.92 (m,
 4H), 4.80 (m, 1H), 4.10 (m, 1H), 3.03 (m, 2H), 2.76 (s, 3H),
 1.8-1.34 (m, 3H), 0.89 (m, 6H), FABMS m/z (558, MH^+).

Example 13

1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-
 10 oxobutyloxy]-5'-chloro-6'-methylbenzotriazole.




Method A; reaction time: 15h; yield 25%;
 purification: HPLC (reverse phase, acetonitrile:water
 (containing 0.1% trifluoroacetic acid) 10%-100% over 40 min)
 15 R_t : 34.06 min; ^1H NMR (300 MHz, CDCl_3): δ 8.00 (s, 1H), 7.70
 (s, 1H), 7.43-6.93 (m, 10H), 6.58 (m, 1H), 5.29 (m, 1H),
 5.15-4.90 (m, 4H), 4.73 (m, 1H), 4.10 (m, 1H), 2.97 (m, 2H),
 2.58 (s, 3H), 1.66-1.30 (m, 3H), 0.89 (m, 6H); FABMS m/z
 (592, MH^+).

- 33 -

Example 14


1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-oxobutyloxy]-4'-chlorobenzotriazole.



5 Method A; reaction time: 3h; yield 19%;
 purification: HPLC (reverse phase, acetonitrile:water
 (containing 0.1% trifluoroacetic acid) 10%-100% over 40 min)
 R_t : 32.13 min; ^1H NMR (300 MHz, CDCl_3): δ 7.75 (d, 1H), 7.49-
 6.86 (series of m, 12H), 6.59 (m, 1H), 5.29 (m, 1H), 5.12-
 10 4.89 (m, 4H), 4.66 (m, 1H), 4.09 (m, 1H), 2.96 (m, 2H),
 1.66-1.29 (m, 3H), 0.89 (m, 6H); FABMS m/z (578, M^+).

Example 15

1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-oxobutyloxy]-6'-phenylbenzotriazole.



15

- 34 -

Method A; reaction time: 15h; yield 3%;

purification: HPLC (reverse phase, acetonitrile:water


(containing 0.1% trifluoroacetic acid) 10%-100% over 40 min)

R_t : 33.23 min; ^1H NMR (300 MHz, CDCl_3): δ 8.02 (m, 2H), 7.79-

5 6.94 (series of m, 16H), 6.63 (m, 1H), 5.30 (bd, 1H), 5.15-
4.9 (m, 4H), 4.77 (m, 1H), 4.12 (m, 1H), 3.00 (m, 2H), 1.7-
1.3 (series of m, 3H), 0.87 (m, 6H); FABMS m/z (620, MH^+).

Example 16

1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-
10 oxobutyloxy]-4',5',6',7'-tetrafluorobenzotriazole.



Method A; reaction time: 15h; yield 4%;

purification: HPLC (reverse phase, acetonitrile:water

(containing 0.1% trifluoroacetic acid) 10%-100% over 40 min)

15 R_t : 33.08 min; ^1H NMR (300 MHz, CDCl_3): δ 7.43-7.00 (m, 10H),
6.57 (m, 1H), 5.35 (bd, 1H), 5.1-4.89 (s overlapping with m,
4H), 4.70 (m, 1H), 4.12 (m, 1H), 3.03 (m, 2H), 1.7-1.2. (m,
3H), 0.92 (m, 6H); FABMS m/z (616, MH^+).

- 36 -

(m, 1H), 5.16-4.88 (s and m, 4H), 4.64 (m, 1H), 4.12 (m, 1H), 3.00 (m, 2H), 1.66-1.3 (m, 3H), 0.92 (m, 6H); FABMS M/Z (614, mh+).

Example 19

5 1-[N-[N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-oxobutyloxy]-(1H)-triazolo[4,5-b]pyridine.

R_t:27.24 min; ¹H NMR (300 MHz, CDCl₃): δ 8.8 (m, 1H), 8.37 (m, 1H), 7.54 (m, 1H), 7.43-6.89 (m, 10H), 6.80 (m, 1H), 5.40 (m, 1H), 5.23-4.97 (s and m, 4H), 4.66 (m, 10 1H), 4.14 (m, 1H), 2.97 (m, 2H), 1.66-1.32 (m, 3H), 0.88 (m, 6H); FABMS m/z (545, MH+).

Example 20

1-[N-[N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-oxobutyloxy]-4',5,6',7'-tetrachlorobenzotriazole.

15 R_t:34.67 min; ¹H NMR (300 MHz, CDCl₃): δ 7.40-7.06 (m, 10H), 6.63 (m, 1H), 5.32 (m, 1H), 5.14-4.91 (s and m, 4H), 4.86 (m, 1H), 4.10 (m, 1H), 3.08 (m, 2H), 1.49-1.2 (m, 3H), 0.89 (m, 6H); FABMS m/z (682, MH+).

- 37 -


Example 21

1- [N- [N-Benzyloxycarbonyl-L-leucyl] -3S-4-phenyl-3-amino-2-oxobutyloxy] -4',6',7'-trichlorotriazole.

R_t : 33.56 min; ^1H NMR (300 MHz, CDCl_3): δ 7.52 (s, 1H), 7.437.00 (m, 10H), 6.57 (m, 1H), 5.28 (bd, 1H), 5.17-4.83 (m, 5H), 4.11 (m, 1H), 3.08 (m, 2H), 1.63-1.2 (m, 3H), 0.85 (m, 6H); FABMS m/z (648, MH^+).

Example 22

1- [N- [N-Benzyloxycarbonyl-L-leucyl] - (3S) -4-phenyl-3-amino-2-oxobutyloxy]benzimidazole.



Method B, reaction time 40 min; purification: HPLC (reverse phase, acetonitrile:water (containing 0.1% trifluoroacetic acid) 10%-100% over 40 min.) R_t : 24.64 min; yield 41%; ^1H NMR (300 MHz, CDCl_3): δ 9.14 (br, 1H), 7.81 (m, 1H), 7.6-7.0 (m, 16H), 5.5-4.9 (m, 3H), 4.59 (m, 1H), 4.10 (m, 1H), 3.00 (m, 2H), 1.53 (m, 1H), 1.40 (m, 2H), 0.83 (2d, 6H); FABMS m/z 543 (MH^+); mp 56-60 C.

Example 23

1- [N- [N-Benzyloxycarbonyl-L-leucyl] -3S-4-phenyl-3-amino-2-

SUBSTITUTE SHEET (RULE 26)

- 38 -

oxobutyloxy]-4',5'-dichlorobenzotriazole.

R_t : 32.70 min; ^1H NMR (300 MHz, CDCl_3): δ 7.63 (d, 1H), 7.46 (d, 1H), 7.32-6.75 (m, 10H), 6.53 (m, 1H), 5.20 (m, 1H), 5.03-4.8 (s and m, 4H), 4.50 (m, 1H), 3.97 (m, 1H),
5 2.80 (m, 2H), 1.45-1.14 (m, 3H), 0.80 (m, 6H); FABMS m/z (614, MH^+).

Example 24

1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-oxobutyloxy]-5'-chloro-6'-ethylbenzotriazole.

10 R_t : 33.90; ^1H NMR (300 MHz, CDCl_3): δ 7.91 (s, 1H), 7.63 (s, 1H), 7.32-6.85 (m, 10H), 6.57 (m, 1H), 5.23 (m, 1H), 5.06-4.86 (s and m, 4H), 4.66 (m, 1H), 4.03 (m, 1H), 3.03-2.8 (m, 4H), 1.57-1.2 (m and t, 6H), 0.80 (m, 6H); FABMS m/z (606, MH^+).

15 Example 25

1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-oxobutyloxy]-4',5'-difluorobenzotriazole.

R_t : 31.54 min; ^1H NMR (300 MHz, CDCl_3): δ 7.63 (m, 1H), 7.51-6.90 (m, 11H), 6.68 (m, 3H), 5.34 (m, 1H), 5.2-
20 4.92 (s and m, 4H), 4.67 (m, 1H), 4.09 (m, 1H), 2.97 (m, 2H), 1.66-1.31 (m, 3H), 0.92 (m, 6H); FABMS m/z (580, MH^+).

Example 26

1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-oxobutyloxy]-6'-methylbenzotriazole.

25 R_t : 31.57 min; ^1H NMR (300 MHz, CDCl_3) δ 7.88 (d,

SUBSTITUTE SHEET (RULE 26)

- 39 -

1H), 7.57 (s, 1H), 7.43-6.94 (m, 11H), 6.67 (m, 1H), 5.25 (d, 1H), 5.11-4.92 (s and m, 4H), 4.80 (m, 1H), 4.11 (m, 1H), 3.03 (m, 2H), 2.59 (s, 3H), 1.66-1.3 (m, 3H), 0.90 (m, 6H); FABMS m/z (558, MH+).

5 Example 27

1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-oxobutyloxy]-5'-methylbenzotriazole.

R_t: 31.59 min; ¹H NMR (300 MHz, CDCl₃): δ 7.74 (m, 2H), 7.43-6.94 (m, 11H), 6.68 (m, 1H), 5.27 (bd, 1H), 5.14-
10 4.91 (s and m, 4H), 4.74 (m, 1H), 4.11 (m, 1H), 3.00 (m, 2H), 2.52 (s, 3H), 1.68-1.3 (m, 3H), 0.86 (m, 6H); FABMS m/z (558, MH+).

Example 28

1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-
15 oxobutyloxy]-3-benzotriazin-4-one.

Method B. reaction time 4h; purification, recrystallization (EtOAc/Hexanes); yield 76%; mp 155-157°C; ¹H-NMR (300 MHz, CDCl₃) δ 8.38 (d, 5 Hz, 1H), 8.22 (d, 5 Hz, 1H), 8.01 (d, 5 Hz, 1H), 7.85 (d, 5 Hz, 1H), 7.35-7.15 (m, 10H), 6.95 (m, 1H), 5.20-4.90 (m, 6H), 4.20-4.10 (m, 1H),
20 3.40-3.30 (m, 1H), 3.20-3.05 (m, 1H), 1.65-1.35 (m 3H), 0.95-0.85 (m, 6H); MS (ESI): 572 (M+H)⁺; Anal, calcd for C₃₁H₃₃N₅O₆: C (65.12), H (5.83), N (12.25); Fd: C (65.06), H (5.74), N (12.39).

25 Example 29

- 40 -

I- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-oxobutyloxy]-3-(6',7'-dimethoxy)benzotriazin-4-one.

Method B. reaction time 5h; purification, recrystallization (EtOAc/Hexanes); yield 73%; mp 180-
5 185°C(dec); ¹H-NMR (300 MHz, CDCl₃): δ 7.61 (s, 1H), 7.52 (s, 1H), 7.35-7.15 (m, 10H), 6.90 (m, 1H), 5.20-4.80 (m, 6H), 4.22-4.10 (m, 1H), 4.05 (2d, 6H), 3.40-3.30 (m, 1H), 3.18-3.05 (m, 1H), 1.65-1.35 (m, 3H), 0.95-0.85 (m, 6H); MS (ESI): 632 (M+H)⁺; Anal, calcd for C₃₃H₃₇N₅O₈: C(62.74),
10 H(5.92), N(11.09); Fd: C(62.51), H(5.76), N(11.03).

Example 30

1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-4-phenyl-3-amino-2-oxobutyloxy]-3-(6'-chloro)benzotriazin-4-one.

Method B. reaction time 4h; purification,
15 recrystallization (EtOAc/Hexanes); yield 57%; mp 150-153°C (dec); ¹H-NMR (300 MHz, CDCl₃): δ 8.35 (s, 1H), 8.15 (d, 5 Hz, 1H), 7.92 (d, 5 Hz, 1H), 7.35-7.15 (m, 10H), 6.90 (m, 1H), 5.15-4.85 (m, 6H), 4.20-4.10 (m, 1H), 3.35-3.25 (m, 1H), 3.15-3.05 (m, 1H), 1.65-1.35 (m 3H), 0.95-0.85 (m, 6H);
20 MS (ESI): 607/609 (M+H)⁺; mono-chloro isotope pattern; Anal, calcd for C₃₁H₃₂N₅O₆Cl: C(61.42), H(5.33), N(11.56), Cl(5.85); Fd: C(61.34), H(5.33), N(11.54), Cl(6.20).

Example 31

1- [N- [N-Benzyloxycarbonyl-L-leucyl]-3S-5-methyl-3-amino-2-
25 oxohexyloxy]-3-benzotriazin-4-one.

Method B. reaction time 21h; purification,


- 41 -

recrystallization (EtOAc/Hexanes); yield 52%; mp 147-148.5°C; $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 8.38 (d, 5 Hz, 1H), 8.22 (d, 5 Hz, 1H), 8.01 (d, 5 Hz, 1H), 7.85 (d, 5 Hz, 1H), 7.35 (m, 5H), 6.80 (m, 1H), 5.20-4.95 (m, 6H), 4.30-4.20 (m, 1H), 1.90-1.50 (m, 6H), 1.00-0.90 (m, 12H); MS (ESI): 538 (M+H) $^+$; Anal, calcd for $\text{C}_{28}\text{H}_{35}\text{N}_5\text{O}_6$: C (62-54), H(6.58), N(13.03); Fd: C(62-43), H(6.52), N(12.96).

Synthesis of Compounds Containing Xanthene-9-yl and 1-phenylpropyl Functionality

10 Synthesis of compounds containing the xanthene-9-yl and 1-phenylpropyl functionality are depicted in Scheme 2.


SCHEME 2



- 42 -

Example 32


Synthesis of Intermediate 1 (Scheme 2):



To a cooled (0°C) solution of xanthene-9-
5 carboxylic acid (9.05g, 0.04 mole) in anhydrous THF (40mL)
was added 1,1' carbonyldiimidazole (6.81g, 0.042 mole). The
mixture was stirred at 0°C for 0.5h and then at room
temperature overnight. The next day, this solution was
added slowly, over 1h, to a cooled (-78°C) solution of tert-
10 butyl lithioacetate (0.088 mole, generated, in situ from
tert-butyl acetate and lithium diisopropylamide) in THF (40
mL) hexane (35 mL). The mixture was stirred for an
additional 0.5h, quenched with 1N HCl (88 mL), brought to
0°C and acidified with 1N HCl to pH 3-4. The resulting
15 aqueous solution was extracted with ethyl acetate (2x 100
mL). The organic layer was washed with brine, dried over
anhydrous sodium sulfate, and the solvent was removed under
reduced pressure. Purification by flash chromatography
(silica gel, 6% ethyl acetate-hexane) gave 8.7g of the
20 desired product: ¹H-NMR (300 MHz, CDCl₃) δ 7.40-7.00 (m, 8H),
5.00 (s, 1H), 3.20 (s, 1H) 1.40 (s, 9H). A general
description of this procedure can be found in Harris, B.D.
et al., *Tetrahedron Lett.* 28(25) 2837 (1987), and in Hamada,

- 43 -

Y. et al., *J. Am. Chem. Soc.* 111, 669 (1989).

Example 33**Synthesis of Intermediate 2 (Scheme 2):**

5 To a stirred slurry of 60% sodium hydride in oil (0.860g, 0.0215 mol) in anhydrous THF (10 mL), was added slowly the keto ester Intermediate 1 (6.63g, 0.02 mol) in anhydrous THF (20 mL). After the evolution of hydrogen gas ceased, the solution was treated with 6.82g of the leucine-


10 triflate methyl ester (generated from the corresponding (D)-hydroxyester (4.00g) and triflic anhydride (8.05g) in the presence of 2,6-lutidine (3.06g)) adapted from the procedure described in Hoffman, R.V. et al., *Tetrahedron Lett.* 34(13), 2051 (1993). The resulting mixture was stirred overnight,

15 diluted with ether (100 mL) washed with water (30 mL) and concentrated under reduced pressure to give 7.00g of crude diester intermediate. This material was then dissolved in trifluoroacetic acid (TFA, 7 mL) and stirred at room temperature for 1hr. The TFA was removed and the residue

20 dissolved in benzene (30 mL) and heated at reflux for 1h. The solvent was removed under reduced pressure and

- 44 -


purification by flash chromatography (silica gel, 4% ethyl acetate-hexane) gave 2.34g of the product, Intermediate 2: ^1H NMR (300MHz, CDCl_3) δ 7.40-7.0 (m, 8H), 4.90 (s, 1H), 3.55 (s, 3H), 2.80-2.60 (m, 2H), 2.30 (dd, $J=8\text{Hz}$ and 2Hz , 1H),
5 1.30 (m, 2H), 1.00 (m, 1H), 0.80 (d, $J=8\text{Hz}$, 3H), 0.70 (d, $J=8\text{Hz}$, 3H).

Example 34**Intermediate 3 (Scheme 2):**

10 A mixture of Intermediate 2 (2.33g, 6.6 mmol)
lithium hydroxide-monohydrate (0.360g), methanol (27 mL),
and water (9 mL), was heated at 70-75°C for 1.5h. The
methanol was removed under reduced pressure. The resulting
aqueous solution was washed with diethyl ether (20 mL),
15 acidified at 0°C with 1N HCl and then extracted with diethyl
ether (3x10 mL). The organic layer was washed once with
brine and dried over anhydrous sodium sulfate. Filtration
followed by removal of the solvent under reduced pressure
produced 1.83g of the product, Intermediate 3. ^1H -NMR (300
20 MHz, CDCl_3) δ 7.40-7.00 (m, 8H), 4.95 (s, 1H), 2.80-2.60 (m,
2H), 2.30 (dd, $J=8\text{Hz}$ and 2Hz , 1H), 1.35 (m, 1H), 1.00 (m,

- 45 -


1H), 0.80 (d, J=8Hz, 3H), 0.70 (d, J=8Hz, 3H).

Example 35**Intermediate 4 (Scheme 2):**

5 To a cooled (-60°C) solution of Intermediate 3 [0.148g, 0.4373 mmol] in anhydrous THF (3 mL) was added N-methylmorpholine (0.142g) followed by isobutyl chloroformate (0.066g). The mixture was stirred for 0.5h and the cooling bath replaced by an ice-water bath. To the reaction mixture
10 was added 0.012g of phenylalanine chloromethyl ketone hydrochloride in DMF (3 mL). The resulting mixture was stirred at 0°C for 1h then at room temperature overnight. The mixture was then diluted with ethyl acetate (20 mL), washed with 2% aqueous citric acid (2 x 10mL), 2% aqueous
15 NaHCO₃ (2 x 10mL), brine (1 x 10mL), and dried over anhydrous sodium sulfate. Filtration and removal of the solvent under reduced pressure gave crude Intermediate 4. Purification by flash chromatography (silica gel, 15% ethyl acetate/hexane) afforded 0.105g of Intermediate 4. ¹H-NMR (300MHz, CDCl₃), δ
20 7.10-7.30 (m, 13H), 6.15 (d, J=6Hz, 1H), 4.90 (s, 1H), 4.70 (q, J=6Hz, 1H), 4.05 (d, J=16Hz, 1H), 3.85 (d, J=16Hz, 1H),

- 46 -

3.00 (m, 1H), 2.50 (m, 2H), 2.30 (dd, J=8Hz and 2Hz, 1H),
1.30 (m, 2H), 0.90 (m, 1H), 0.75 (d, J=6Hz, 3H), 0.65 (d,
J=6Hz, 3H).

Example 36**5 Intermediate 5 (Scheme 2):**

Following the same procedure described for the
synthesis of Intermediate 4, Intermediate 3 [0.408g, 1.205
mmol] was coupled with leucine chloromethyl ketone
10 hydrochloride (0.241g) to yield 5 (0.146g): ¹H-NMR (300MHz,
CDCl₃) δ 7.40-7.00 (m, 8H), 6.00 (d, J=8HZ, 1H), 4.90 (s,
1H), 4.60 (m, 1H), 4.20 (s, 2H), 2.70-2.50 (m, 2H), 2.35
(dd, J=8HZ and 2Hz, 1H), 1.60-1.20 (m, 4H), 0.95 (d, J=8Hz,
3H), 0.90 (m, 2H), 0.85 (d, J=8Hz, 3H), 0.80 (d, J=8Hz, 3H),
15 0.70 (d, J=8HZ, 3H).

Example 37**Intermediate 6 (Scheme 2)**

A mixture of Intermediate 4 (0.030g, 0.058mmol),
sodium iodide (0.022g) and acetone (3 mL) was stirred at
20 room temperature for 1h. The solvent was removed under

- 47 -


reduced pressure and the residue was partitioned between H₂O (5mL) and CH₂Cl₂ (2 x 5mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure, to give 0.036g of Intermediate 6: ¹H-NMR (300MHz, CDCl₃) δ 7.40-7.00 (m, 13H), 6.15 (d, J=6Hz, 1H), 4.90 (s, 1H), 4.85 (q, J=6Hz, 1H), 3.70 (d, J=8Hz, 1H), 3.60 (d, J=8Hz, 1H), 3.00 (m, 2H), 2.50 (m, 2H), 2.30 (dd, J=8Hz and 2Hz, 1H), 1.30 (m, 2H), 0.85 (m, 1H), 0.75 (d, J=6Hz, 3H), 0.65 (d, J=6Hz, 3H).

10 **Example 38****Intermediate 7 (Scheme 2):**

Following the same procedure described for the synthesis of Intermediate 6, Intermediate 5 (0.105g, 0.217 mmol) was converted to Intermediate 7 (0.120g): ¹H-NMR (300MHz, CDCl₃) δ 7.40-7.00 (m, 8H), 6.00 (d, J=8Hz, 1H), 4.90 (s, 1H), 4.70 (m, 1H), 3.90 (d, J=6Hz, 1H), 3.85 (d, J=6Hz, 1H), 2.70-2.50 (m, 2H), 2.35 (dd, J=8Hz and 2Hz, 1H), 1.60-1.20 (m, 4H), 0.95 (d, J=8Hz, 3H), 0.90 (m, 2H), 0.85 (d, J=8Hz, 3H), 0.80 (d, J=8Hz, 3H), 0.75 (d, J=8Hz, 3H).

20 **Example 39**

1-[N-[2-(2-Methylpropyl)-1,4-dioxo-4-(xanthen-9-yl)butyl]-3S-3-amino-2-oxo-4-phenylbutyloxy]benzotriazole.




- 48 -

Using method A, Intermediate 6 (0.046g, 0.075 mmol) was coupled with 1-hydroxybenzotriazole (0.014g) to give the product (0.046g) as a white solid after purification by crystallization from ethyl acetate-hexane:

5 mp 99-101 °C; FABMS 618 m/z (M⁺); ¹HNMR (300MHz, CDCl₃) δ 8.00 (d, J=6Hz, 1H), 7.80 (d, J=6Hz, 1H), 7.70 (t, J=6Hz, 1H), 7.00 (t, J=6Hz, 1H), 7.30-6.90 (m, 13H), 6.10 (d, J=8Hz, 1H), 5.15 (d, J=16Hz, 1H), 4.90 (d, J=16Hz, 1H), 4.85 (s, 1H), 4.55 (m, 1H), 2.90 (m, 2H), 2.50 (m, 2H), 2.30 (dd, 10 J=8Hz and 2Hz, 1H), 1.30 (m, 2H), 0.85 (m, 1H), 0.75 (d, J=6Hz, 3H), 0.65 (d, J=6Hz, 3H).

Example 40

1- [N[- [2- (2-Methylpropyl) -1,4-dioxo-4- (xanthen-9-yl)butyl] - 3S-3amino-5-methyl-2-oxohexyloxy]benzotriazole.




15


Using method A, Intermediate 7 (0.115g, 0.2 mmol) was coupled with 1-hydroxybenzotriazole (0.034g) to give the compound (0.051g) as a white solid: m.p. 92-94 °C; ¹H-NMR (300MHz, CDCl₃); δ 8.00 (d, J=6Hz, 1H), 7.80 (d, J=6Hz, 1H), 7.65 (t, J=7Hz, 1H), 7.40 (t, J=7Hz, 1H), 7.35-7.00 (m, 8H), 6.00 (d, J=8Hz, 1H), 5.40, (s, 2H), 4.90 (s, 1H), 4.50 (m, 20

- 49 -

1H) δ 2.70-2.50 (m, 2H), 2.30 (dd, $J=8\text{Hz}$ and 2H, 1H), 1.60-1.20 (m, 4H), 0.95 (d, $J=8\text{Hz}$, 3H), 0.90 (m, 2H), 0.85 (t, $J=8\text{Hz}$, 3H), 0.80 (d, $J=8\text{Hz}$, 3H), 0.75 (d, $J=8\text{Hz}$, 3H).

Example 41**5 Synthesis of Intermediate 1a (Scheme 2)**


Following the same method for the synthesis of the Intermediate 1 of Example 32 ($R'=9\text{-xanthenyl}$), (S)-(+)-2-phenylbutyric acid (3.93g, 0.024 mole) was converted to Intermediate 1a, $R'=1\text{-phenylpropyl}$ (4.13g): $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 7.38-7.18 (m, 5H), 3.70 (t, $J=6\text{Hz}$, 1H), 3.35 (d, $J=16\text{Hz}$, 1H), 3.20 (d, $J=16\text{Hz}$, 1H), 2.10 (m, 1H), 2.70 (m, 1H), 1.45 (s, 9H), 0.85 (t, $J=17\text{Hz}$, 3H).

Example 42**Synthesis of Intermediate 2a (Scheme 2)**


15 Following the same method for the synthesis of the Intermediate 2 of Example 33, ($R'=9\text{-xanthenyl}$), Intermediate

- 50 -

1a (3.25g, 0.0124 mole) was converted to Intermediate 2a (2.85g): ^1H NMR (300 MHz, CDCl_3) δ 7.40-7.18 (m, 5H), 3.60 (s, 3H), 3.50 (t, $J=6\text{Hz}$, 1H), 2.85 (m, 1H), 2.75 (m, 1H), 2.45 (dd, $J=18\text{Hz}$ and 2Hz , 1H), 2.05 (m, 1H), 1.70 (m, 1H), 1.45 (m, 2H), 1.15 (m, 1H), 0.90-0.70 (m, 9H).

Example 43**Synthesis of Intermediate 3a (Scheme 2)**

Intermediate 2a (0.570g, 1.963 mmol) was hydrolyzed to Intermediate 3a ($R' = 1\text{-phenylpropyl}$) (0.507g), following the same procedure for the synthesis of Intermediate 3 of Example 34 ($R' = 9\text{-xanthenyl}$): ^1H NMR (300 MHz, CDCl_3) δ : 7.40-7.10 (m, 5H), 3.60 (m, 1H), 2.90 (m, 1H), 2.75 (m, 1H), 2.50 (m, 1H), 2.05 (m, 1H), 1.70 (m, 1H), 1.50 (m, 2H), 1.15 (m, 1H), 0.90-0.70 (m, 9H).

Example 44.**Synthesis of Intermediate 4a (Scheme 2)**

Following the same procedure for the synthesis of Intermediate 4 of Example 35 ($R' = 9\text{-xanthenyl}$, $R = \text{benzyl}$),

- 51 -

Intermediate 3a (0.386g, 1.40 nmol) was converted to Intermediate 4a (R'=1-phenylpropyl, R=benzyl) (0.382g, 72:28 diastereomeric mixture): ¹HNMR (300 MHz, CDCl₃) δ 7.40-7.10 (m, 10H), 6.30 (d, J=6Hz, 1H), 4.85 and 4.75 (2 set of q, 5 72:28, J=6Hz, 1H), 4.10 and 4.05 (2 sets of doublet, 72:28, J=18Hz, 1H), 3.90 and 3.85 (2 sets of doublet, 72:28, J=18Hz, 1H), 3.50 (m, 1H), 3.10 (m, 1H), 2.95 (m, 1H), 2.65 (m, 2H), 2.40 (m, 1H), 2.00 (m, 1H), 1.70 (m, 1H), 1.35 (m, 2H), 1.00 (m, 1H), 0.90-0.65 (m, 9H).


10 **Example 45****Synthesis of Intermediate 5a (Scheme 2)**

0.087g (0.1907 mmol) of Intermediate 4a, R'=1-phenylpropyl, R=benzyl, was converted to Intermediate 5a (R'=1-phenylpropyl, R=benzyl) (0.094g, 72:28 diastereomeric 15 mixture) following the same procedure for the synthesis of Intermediate 6 of Example 36, (R'=9-xanthenyl, R=benzyl): ¹HNMR (300 MHz, CDCl₃) δ 7.40-7.10 (m, 10H), 6.30 (mixture of doublets, 1H), 5.00 and 4.85 (2 sets of quartets, 72:28, J=6Hz, 1H), 3.75 and 3.65 (2 sets of doublets, 72:28, 20 J=16Hz, 1H), 3.70 and 3.60 (2 sets of doublets, 72:28, J=16Hz, 1H), 3.50 (m, 1H), 3.10 (d, J=6Hz, 1H), 3.00 (m, 1H), 2.65 (m, 2H), 2.40 (m, 1H), 2.00 (m, 1H), 1.70 (m, 1H), 1.40 (m, 2H), 1.00 (m, 1H), 0.85-0.70 (m, 9H).

- 52 -

Example 46

1- [N- [2R- (2-methylpropyl) -1,4-dioxo-5S-phenylheptan-1-yl] -
3S-3-amino-2-oxo-4-phenylbutyloxy]benzotriazole



Following method A, Intermediate 5a, (0.094g,
5 0.1716 mmol) was coupled with 1-hydroxybenzotriazole
(0.030g) to give 1- [N- [2R- (2-methylpropyl) -1,4-dioxo-5S-
phenylheptan-1-yl] -3S-3-amino-2-oxo-4-
phenylbutyloxy]benzotriazole (0.080g) as a mixture (72:28)
of diastereomers: ¹HNMR (300 MHz, CDCl₃) δ 8.00 (d, J=6Hz,
10 1H), 7.85 and 7.80 (2 sets of doublets, 72:28, J=6Hz, 1H),
7.55 (t, J=6Hz, 1H), 7.40 (t, J=6Hz, 1H), 7.30-6.20 (m,
10H), 6.25 (mix. of doublets, 1H), 5.30 and 5.20 (2 sets of
doublets, 72:28, J=16Hz, 1H), 4.95 and 4.90 (2 sets of
doublets, 72:28. J=6HZ, 1H), 4.70 and 4.50 (2 sets of
15 quartet, 72:28, J=7Hz, 1H), 3.50 (m, 1H), 3.00 and 2.90 (2
sets of doublets, 72:28, J=8Hz, 1H), 2.60 (m, 2H), 2.40 (m,
1H), 2.00 (m, 1H), 1.65 (m, 2H), 1.30 (m, 1H), 0.90 (m, 1H),
0.85-0.60 (m, 9H).

Each of the published documents mentioned in this
20 specification is hereby incorporated by reference in their
entirety.

Those skilled in the art will appreciate that


- 53 -

numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the
5 appended claims cover all equivalent variations as fall within the true spirit and scope of the invention.

- 54 -

WHAT IS CLAIMED IS:

1. A compound represented by the formula:



wherein:

M is selected from the group consisting of O, NR⁷
 5 and CR¹R².

X¹ is selected from the group consisting of O, S
 and NR⁷;

X² is selected from the group consisting of O, S,
 N⁷ and two hydrogen atoms;

10 Q is selected from the group consisting of O, S
 and NR¹;

R¹ and R² are each independently selected from the
 group consisting of H, alkyl having from 1 to 10 carbons,
 heteroaryl having from 1 to 10 carbons, alkanoyl having from
 15 1 to 10 carbons, and aroyl, wherein said alkyl, heteroaryl,
 alkanoyl and aroyl groups are optionally substituted with J;

R³, R⁴, R⁵ and R⁶ are each independently selected
 from the group consisting of H, alkyl having from 1 to 10
 carbons, aryl, and heteroaryl, wherein said alkyl, aryl and
 20 heteroaryl groups are optionally substituted with J;

R⁷ and R⁸ are each independently selected from the
 group consisting of H, alkyl having from 1 to 10 carbons,
 aryl, and heteroaryl, wherein said alkyl, aryl and
 heteroaryl groups are optionally substituted with J;

- 55 -


J is selected from the group consisting of halogen, COOR⁷, R⁷OCO, R⁷OCONH, OH, CN, NO₂, NR⁷R⁸, N=C(R⁷)R⁸, N=C(NR⁷R⁸)₂, SR⁷, OR⁷, phenyl, naphthyl, heteroaryl, and a cycloalkyl group having from 3 to 8 carbons;

- 5 G is selected from the group consisting of NH₂, NHR¹, CH₂R¹, CH₂C(O)B, carbobenzyloxy-NH, succinyl-NH, R⁷O-succinyl-NH, R⁷OC(O)NH, CH₂C(O)-(xanthen-9-yl), CH₂COR⁷ wherein R⁷ is selected from the group consisting of alkyl, aryl, and arylalkyl group of up to 13 carbons, and
- 10 AA'NHC(O)OCH₂C₆H₅, wherein AA' is selected from the group consisting of one of the 20 natural amino acids and an opposite antipode of said amino acid;

B is selected from the group consisting of alkyl having from 1 to 10 carbons, aralkyl having from 1 to 10 carbons, aryl having 1 to 3 carbocyclic rings, and

15 heteroaryl having 1 to 3 rings, wherein said alkyl, aralkyl, aryl and heteroaryl groups are optionally substituted with J; and

A is represented by the structure:



20

wherein:

Y is selected from the group consisting of N and CR¹;

W is selected from the group consisting of a

- 56 -


double bond and a single bond;

D is selected from the group consisting of C=O and a single bond;

E and F are each independently selected from the group consisting of R¹, R², J, and when E and F comprise a joined moiety, said moiety is selected from the group consisting of an aliphatic carbocyclic ring having from 5 to 7 carbons, an aromatic carbocyclic ring having from 5 to 7 carbons, an aliphatic heterocyclic ring having from 5 to 7 atoms, and an aromatic heterocyclic ring having 5 to 7 atoms; wherein:

said aliphatic heterocyclic ring and said aromatic heterocyclic ring each have from 1 to 4 heteroatoms; and said aliphatic carbocyclic ring, said aromatic carbocyclic ring, said aliphatic heterocyclic ring, and said aromatic heterocyclic ring are each optionally substituted with J.

2. The compound of formula 1 represented by the formula:



20 wherein:


K is selected from the group consisting of NHC(O)OCH₂C₆H₅,

- 57 -

$-\text{CH}_2\text{C}(\text{O})-(\text{xanthen-9-yl})$ and $-\text{C}_2\text{C}(\text{O})\text{CH}(\text{C}_6\text{H}_5)\text{C}_2\text{H}_5$;

P^1 is selected from the group consisting of isobutyl, isopropyl, benzyl, carboxyalkyl of 2-9 carbons and ethyl; and

5 X^3 is represented by the structure:



wherein:

D is selected from the group consisting of $\text{C}=\text{O}$ and a single bond;

10 X^4 is selected from the group consisting of CH , CCl , CCH_3 , CF and N ;

X^5 is selected from the group consisting of H , CH_3 , Cl , OCH_3 and F ;

X^6 is selected from the group consisting of H , CH_3 , Cl , F ,

OCH_3 , CF_3 , ethyl and phenyl;

X , is selected from the group consisting of N , CCl , CH , COCH_3 and CF ; and

- 58 -

Y is selected from the group consisting of N and CH.

3. The compound of claim 2 wherein K is $-\text{CH}_2\text{C}(\text{O})-$ (xanthen-9yl).

5 4. The compound of claim 2 wherein P' is benzyl.

5. The compound of claim 4 wherein Y is N.

6. The compound of claim 4 wherein X³ is O-1-oxybenzotriazole.

7. The compound of claim 2 wherein X⁷ is N.

10 8. The compound of claim 2 wherein Y is CH.

9. The compound of claim 1 wherein Q is NR¹.

10. The compound of claim 1 wherein one of R¹ or R² is other than H.

11. The compound of claim 1 wherein X¹ is
15 selected from the group consisting of S and NR⁷.


12. The compound of claim 1 wherein neither of R³ and R⁴ are H.

- 59 -

13. The compound of claim 1 wherein M is selected from the group consisting of O and CR¹R².

14. The compound of claim 1 wherein X² is selected from the group consisting of S, NR⁷, and two hydrogen atoms.

15. The compound of claim 2 wherein K has the formula:



16. A composition for inhibiting the enzymatic activity of a serine protease or a cysteine protease comprising a compound of claim 1.

17. A method for inhibiting the enzymatic activity of a serine protease or cysteine protease comprising contacting a protease selected from the group consisting of serine protease and cysteine protease with an

- 60 -

inhibitory amount of a compound of claim 1.

18. A method for inhibiting the enzymatic activity of a serine protease or cysteine protease comprising contacting a protease selected from the group
5 consisting of serine protease and cysteine protease with an inhibiting amount of a compound of claim 2.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/14794

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE - structure search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,816,482 (OIRY et al.) 28 March 1989	1-18

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be part of particular relevance	* X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)	* A*	document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means		
* P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

09 FEBRUARY 1996

Date of mailing of the international search report

27 FEB 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RICHARD L. RAYMOND

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/14794

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 31/41, 31/415, 31/505, 31/55; C07D 233/02, 235/22, 239/06, 239/70, 407/12, 471/04

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

514/242, 243, 256, 259, 300, 303, 359, 395, 398; 544/182, 183, 184, 275, 287, 319; 546/117, 118; 548/255, 259, 305.1, 309.7, 310.1, 311.4, 336.1 338.1, 341.1, 341.5, 342.1

B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

514/242, 243, 256, 259, 300, 303, 359, 395, 398; 544/182, 183, 184, 275, 287, 319; 546/117, 118; 548/255, 259, 305.1, 309.7, 310.1, 311.4, 336.1 338.1, 341.1, 341.5, 342.1